Palatin Technologies, Inc. (AMEX:PTN) is reporting first quarter financial results on Tuesday 17th November 2020, before market open.
According to analysts surveyed by Thomson Reuters, PTN is expected to report 1Q21 loss of $ 0.03 per share from revenue of $ 1.00 million.
For the full year, analysts anticipate top line of $ 8.28 million, while looking forward to loss of $ 0.12 per share bottom line.
Stock Performance
Shares of Palatin Technologies, Inc. traded up $ 0.02 or 3.78 percent on Monday, reaching $ 0.41 with volume of 1.17 million shares. Palatin Technologies, Inc. has traded high as $ 0.42 and has cracked $ 0.40 on the downward trend
According to the previous trading day, closing price of $ 0.41, representing a 11.11 % increase from the 52 week low of $ 0.36 and a 52.38 % decrease over the 52 week high of $ 0.84.
The company has a market capital of $ 95.18 million and is part of the Healthcare sector and Diagnostics & Research industry.
Conference Call
Palatin Technologies, Inc. will be hosting a conference call at 11:00 AM eastern time on 17th November 2020, to discuss its 1Q21 financial results with the investment community. The participants may dial, 1-800-353-6461 Toll Free or 1-334-323-0501 (International), when prompted, enter passcode 3383273 in order to access the live audio call. A live webcast with presentations will be available on the Internet by visiting the Company website www.palatin.com
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted, receptor-specific therapeutics for the treatment of various diseases in the United States. The companys principal product is Vyleesi, an on demand subcutaneous injectable product that has completed Phase III clinical studies for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. Its drug development programs also include melanocortin receptor system program, such as PL-8177, a selective melanocortin receptor 1 agonist peptide for inflammatory bowel diseases; and PL-8331, a preclinical development candidate for treating ocular inflammation, as well as melanocortin receptor 4 peptides and orally-active small molecules to treat genetic metabolic and obesity disorders.
